Malignant lymphoma of the uterine cervix treated by neoadjuvant chemotherapy.
- Author:
Soon Ho HWANG
1
;
Bo Yeon KIM
;
Jin Hee PARK
;
Kyung Eun LEE
;
Min A LEE
;
Ki Hwan LEE
;
Heung Tae NOH
;
Sung Kyong SON
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Chungnam National University, Daejon, Korea. gustohwang@hanmail.net
- Publication Type:Case Report
- Keywords:
Lymphoma;
Cervical lymphoma;
Neoadjuvant chemotherapy
- MeSH:
B-Lymphocytes;
Cervix Uteri*;
Consensus;
Diagnosis;
Doxorubicin;
Drug Therapy*;
Female;
Humans;
Hysterectomy;
Lymphoma*;
Lymphoma, Non-Hodgkin;
Middle Aged;
Prognosis;
Rare Diseases;
Vincristine
- From:Korean Journal of Gynecologic Oncology
2007;18(2):160-164
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Non-Hodgkin's lymphoma presented as a malignancy of the uterine cervix is exceedingly rare disease and accounts for approximately only 0.12-0.6% of extranodal lymphomas. There is no consensus on the management and prognosis of the disease because of its extreme rarity. Previously, treatment of this disease has been radiation therapy, surgery or chemotherapy either alone or in combination. We present the case of a 45-year-old woman diagnosed with diffuse, large B-cell non-Hodgkin's lymphoma of the uterine cervix. We administered neoadjuvant chemotherapy according to CHOP protocol (cyclophosphamide, adriamycin, vincristine, and prednisone) followed by hysterectomy and bilateral salpingo-oophorectomy. The patient is alive 20 months after the initial diagnosis. We report the case with a brief review of literature.
